Conference report: Voclosporin demonstrated efficacy across lupus nephritis biopsy classes

Efficacy data from pooled analysis for volcosporin in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids vs without voclosporin from AURA-LV and AURORA 1 pivotal trials show potential to improve renal response regardless of disease progression at diagnosis

SPS commentary:

Volclosporin is a modified calcineurin inhibitor which is approved in the US with plans to file in EU in quarter 2 of 2021. It is currently in phase 3 trials.

Biospace Inc.